Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma

Seok Jin Kim, Kihyun Kim, Byung Soo Kim, Hyo Jin Lee, Hawk Kim, Na Ri Lee, Seung Hyun Nam, Jung Hye Kwon, Hyo Jung Kim, Sang Kyun Sohn, Jong Ho Won, Jae Hoon Lee, Cheolwon Suh, Sung Soo Yoon, Hye Jin Kim, Inho Kim, Young Rok Do, Won Sik Lee, Young Don Joo, Ho Jin Shin

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Bortezomib has significantly advanced the treatment of patients with multiple myeloma (MM). However, considering that most patients with MM are elderly, bortezomib-related morbidity should be thoroughly studied to ensure the safe use of this drug. Herpes zoster has been reported as a possible adverse event associated with bortezomib because a major target of bortezomib, nuclear factor-κB, is known to be involved with T-cell immunity. Patients and Methods: We performed a retrospective analysis of the incidence of herpes zoster among 282 patients treated with a bortezomib-containing regimen. Results: During the patients' pre-bortezomib treatment (median, 2.14 years), the incidence of herpes zoster was 11% (31 of 282 patients). However, after the patients were treated with bortezomib, the incidence increased to 22.3% (63 of 282 patients), of which almost all occurrences were within the first 3 cycles (median duration, 41 days). The time interval from diagnosis to bortezomib initiation date was shorter in herpes zoster-positive patients than in herpes zoster-negative patients (2.14 ± 1.87 years vs. 3.38 ± 2.95 years; P = .002). Disease duration, previous herpes zoster infection, disease stage and type of myeloma, and the type and intensity of previous treatments failed to show any relationship with herpes zoster. These findings suggest that longer history of disease and treatments did not affect the occurrence of herpes zoster, nor did the type of bortezomib regimens or their toxicities. Conclusion: Bortezomib can increase the incidence of herpes zoster regardless of disease duration, previous treatments, and concomitantly administered drugs. Thus, the occurrence of herpes zoster should be monitored during bortezomib treatment.

Original languageEnglish
Pages (from-to)237-240
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume8
Issue number4
DOIs
Publication statusPublished - 2008 Aug 1

Fingerprint

Herpes Zoster
Multiple Myeloma
Incidence
Bortezomib
Therapeutics
Pharmaceutical Preparations
Immunity
Morbidity
T-Lymphocytes

Keywords

  • Dexamethasone
  • Melphalan
  • Nuclear factor-κB
  • Postherpetic neuralgia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. / Kim, Seok Jin; Kim, Kihyun; Kim, Byung Soo; Lee, Hyo Jin; Kim, Hawk; Lee, Na Ri; Nam, Seung Hyun; Kwon, Jung Hye; Kim, Hyo Jung; Sohn, Sang Kyun; Won, Jong Ho; Lee, Jae Hoon; Suh, Cheolwon; Yoon, Sung Soo; Kim, Hye Jin; Kim, Inho; Do, Young Rok; Lee, Won Sik; Joo, Young Don; Shin, Ho Jin.

In: Clinical Lymphoma and Myeloma, Vol. 8, No. 4, 01.08.2008, p. 237-240.

Research output: Contribution to journalArticle

Kim, SJ, Kim, K, Kim, BS, Lee, HJ, Kim, H, Lee, NR, Nam, SH, Kwon, JH, Kim, HJ, Sohn, SK, Won, JH, Lee, JH, Suh, C, Yoon, SS, Kim, HJ, Kim, I, Do, YR, Lee, WS, Joo, YD & Shin, HJ 2008, 'Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma', Clinical Lymphoma and Myeloma, vol. 8, no. 4, pp. 237-240. https://doi.org/10.3816/CLM.2008.n.031
Kim, Seok Jin ; Kim, Kihyun ; Kim, Byung Soo ; Lee, Hyo Jin ; Kim, Hawk ; Lee, Na Ri ; Nam, Seung Hyun ; Kwon, Jung Hye ; Kim, Hyo Jung ; Sohn, Sang Kyun ; Won, Jong Ho ; Lee, Jae Hoon ; Suh, Cheolwon ; Yoon, Sung Soo ; Kim, Hye Jin ; Kim, Inho ; Do, Young Rok ; Lee, Won Sik ; Joo, Young Don ; Shin, Ho Jin. / Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. In: Clinical Lymphoma and Myeloma. 2008 ; Vol. 8, No. 4. pp. 237-240.
@article{8ac1c1bb02e4436f859641f1cc6a469a,
title = "Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma",
abstract = "Bortezomib has significantly advanced the treatment of patients with multiple myeloma (MM). However, considering that most patients with MM are elderly, bortezomib-related morbidity should be thoroughly studied to ensure the safe use of this drug. Herpes zoster has been reported as a possible adverse event associated with bortezomib because a major target of bortezomib, nuclear factor-κB, is known to be involved with T-cell immunity. Patients and Methods: We performed a retrospective analysis of the incidence of herpes zoster among 282 patients treated with a bortezomib-containing regimen. Results: During the patients' pre-bortezomib treatment (median, 2.14 years), the incidence of herpes zoster was 11{\%} (31 of 282 patients). However, after the patients were treated with bortezomib, the incidence increased to 22.3{\%} (63 of 282 patients), of which almost all occurrences were within the first 3 cycles (median duration, 41 days). The time interval from diagnosis to bortezomib initiation date was shorter in herpes zoster-positive patients than in herpes zoster-negative patients (2.14 ± 1.87 years vs. 3.38 ± 2.95 years; P = .002). Disease duration, previous herpes zoster infection, disease stage and type of myeloma, and the type and intensity of previous treatments failed to show any relationship with herpes zoster. These findings suggest that longer history of disease and treatments did not affect the occurrence of herpes zoster, nor did the type of bortezomib regimens or their toxicities. Conclusion: Bortezomib can increase the incidence of herpes zoster regardless of disease duration, previous treatments, and concomitantly administered drugs. Thus, the occurrence of herpes zoster should be monitored during bortezomib treatment.",
keywords = "Dexamethasone, Melphalan, Nuclear factor-κB, Postherpetic neuralgia",
author = "Kim, {Seok Jin} and Kihyun Kim and Kim, {Byung Soo} and Lee, {Hyo Jin} and Hawk Kim and Lee, {Na Ri} and Nam, {Seung Hyun} and Kwon, {Jung Hye} and Kim, {Hyo Jung} and Sohn, {Sang Kyun} and Won, {Jong Ho} and Lee, {Jae Hoon} and Cheolwon Suh and Yoon, {Sung Soo} and Kim, {Hye Jin} and Inho Kim and Do, {Young Rok} and Lee, {Won Sik} and Joo, {Young Don} and Shin, {Ho Jin}",
year = "2008",
month = "8",
day = "1",
doi = "10.3816/CLM.2008.n.031",
language = "English",
volume = "8",
pages = "237--240",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma

AU - Kim, Seok Jin

AU - Kim, Kihyun

AU - Kim, Byung Soo

AU - Lee, Hyo Jin

AU - Kim, Hawk

AU - Lee, Na Ri

AU - Nam, Seung Hyun

AU - Kwon, Jung Hye

AU - Kim, Hyo Jung

AU - Sohn, Sang Kyun

AU - Won, Jong Ho

AU - Lee, Jae Hoon

AU - Suh, Cheolwon

AU - Yoon, Sung Soo

AU - Kim, Hye Jin

AU - Kim, Inho

AU - Do, Young Rok

AU - Lee, Won Sik

AU - Joo, Young Don

AU - Shin, Ho Jin

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Bortezomib has significantly advanced the treatment of patients with multiple myeloma (MM). However, considering that most patients with MM are elderly, bortezomib-related morbidity should be thoroughly studied to ensure the safe use of this drug. Herpes zoster has been reported as a possible adverse event associated with bortezomib because a major target of bortezomib, nuclear factor-κB, is known to be involved with T-cell immunity. Patients and Methods: We performed a retrospective analysis of the incidence of herpes zoster among 282 patients treated with a bortezomib-containing regimen. Results: During the patients' pre-bortezomib treatment (median, 2.14 years), the incidence of herpes zoster was 11% (31 of 282 patients). However, after the patients were treated with bortezomib, the incidence increased to 22.3% (63 of 282 patients), of which almost all occurrences were within the first 3 cycles (median duration, 41 days). The time interval from diagnosis to bortezomib initiation date was shorter in herpes zoster-positive patients than in herpes zoster-negative patients (2.14 ± 1.87 years vs. 3.38 ± 2.95 years; P = .002). Disease duration, previous herpes zoster infection, disease stage and type of myeloma, and the type and intensity of previous treatments failed to show any relationship with herpes zoster. These findings suggest that longer history of disease and treatments did not affect the occurrence of herpes zoster, nor did the type of bortezomib regimens or their toxicities. Conclusion: Bortezomib can increase the incidence of herpes zoster regardless of disease duration, previous treatments, and concomitantly administered drugs. Thus, the occurrence of herpes zoster should be monitored during bortezomib treatment.

AB - Bortezomib has significantly advanced the treatment of patients with multiple myeloma (MM). However, considering that most patients with MM are elderly, bortezomib-related morbidity should be thoroughly studied to ensure the safe use of this drug. Herpes zoster has been reported as a possible adverse event associated with bortezomib because a major target of bortezomib, nuclear factor-κB, is known to be involved with T-cell immunity. Patients and Methods: We performed a retrospective analysis of the incidence of herpes zoster among 282 patients treated with a bortezomib-containing regimen. Results: During the patients' pre-bortezomib treatment (median, 2.14 years), the incidence of herpes zoster was 11% (31 of 282 patients). However, after the patients were treated with bortezomib, the incidence increased to 22.3% (63 of 282 patients), of which almost all occurrences were within the first 3 cycles (median duration, 41 days). The time interval from diagnosis to bortezomib initiation date was shorter in herpes zoster-positive patients than in herpes zoster-negative patients (2.14 ± 1.87 years vs. 3.38 ± 2.95 years; P = .002). Disease duration, previous herpes zoster infection, disease stage and type of myeloma, and the type and intensity of previous treatments failed to show any relationship with herpes zoster. These findings suggest that longer history of disease and treatments did not affect the occurrence of herpes zoster, nor did the type of bortezomib regimens or their toxicities. Conclusion: Bortezomib can increase the incidence of herpes zoster regardless of disease duration, previous treatments, and concomitantly administered drugs. Thus, the occurrence of herpes zoster should be monitored during bortezomib treatment.

KW - Dexamethasone

KW - Melphalan

KW - Nuclear factor-κB

KW - Postherpetic neuralgia

UR - http://www.scopus.com/inward/record.url?scp=60849134037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849134037&partnerID=8YFLogxK

U2 - 10.3816/CLM.2008.n.031

DO - 10.3816/CLM.2008.n.031

M3 - Article

VL - 8

SP - 237

EP - 240

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 4

ER -